Investment & Fund Management
and recently South Korea. The company manages all stages of system
Full Credential Description
In 2011, Karl Maier, an economist and expert in energy projects, acquired ZETA Biopharma, a company specializing in integrated system solutions for liquid processes in the biotechnology and pharmaceutical sectors. ZETA Biopharma operates globally, with a presence in Europe, Russia, China, South-East Asia, and recently South Korea. The company manages all stages of system management, including design, engineering, manufacturing, installation, quality control, and maintenance, focusing on processes such as vaccine production and food processing.
To support ZETA Biopharma's growth, particularly in software development and staff training, Karl sought additional financing from UniCredit Bank Austria. The bank provided a loan backed by the European Investment Fund (EIF) under the Investment Plan for Europe, which aims to stimulate investments in small and medium-sized enterprises across Europe. This financing allowed ZETA Biopharma to maintain liquidity in its balance sheet, enabling the company to address immediate financial needs while planning for long-term growth. The favorable terms of the loan were crucial for the company's operational stability and expansion efforts.